News

CSL Completes Transaction to Acquire a Majority Stake in Chinese Plasma Fractionator

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has closed a joint venture transaction with Humanwell Healthcare Group Co. Ltd. (Humanwell; Shanghai exchange: 600079) to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological…

MRFF Grant Round Open

The National Health and Medical Research Council (NHMRC) is administering two competitive grant opportunities on behalf of the Department of Health for programs under the Medical Research Future Fund. Lifting Clinical Trials and Registry Capacity – Grant Opportunity…

August/September Funding & Program Update

Future Industries Manufacturing Program: Grants of up to $500,000 are available to assist companies to implement new manufacturing technologies and processes that will provide a critical foundation for growth. All grants must be matched by a minimum cash co-contribution of…

Regenerative Medicine Industry Interface – a new industry collaboration in Victoria

Announcing RMI2 The Regenerative Medicine Industry Interface Regenerative Medicine An emerging field of medical science, regenerative medicine incorporates the use of cells, factors, and other biological building blocks, along with bioengineered materials and technologies for widespread clinical applications.…

27th March 2018 Devices + Diagnostics Lab – Disruptive Diagnostics

We’re pleased to announce that the theme for our annual Devices + Diagnostics Lab – one day symposium on Tuesday 27th March 2018 – will be “Disruptive Diagnostics”. The program will cover hot topics across the product development…

New collaboration for Alzheimer’s Research – SVI & Janssen

SVI has entered into a collaboration and license agreement with Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceuticals Companies of Johnson & Johnson. The partnership is aimed at developing and commercialising small molecule modulators of microglial function…

Positive Data from Cynata MSCs in Second Preclinical Asthma Study

Positive Data from Cynata MSCs in Second Preclinical Asthma Study • Clear efficacy data for Cynata’s proprietary Cymerus™ MSCs in second preclinical study in a clinically-relevant model of asthma • Cymerus MSCs caused significantly greater reduction of airway…

An Australian first: Monash launches new Diabetes Department

Monash University today officially launched its new Department of Diabetes – the first and only university department in Australia dedicated to the disease. Opened by the Honourable Greg Hunt MP, Minister for Health, the new Department is a…

Global Connections Fund Bridging Grant Awardees 2017

The Global Connections Fund is an initiative of the Australian Government’s National Innovation and Science Agenda (NISA) funded by the Department of Industry, Innovation and Science. You can see Bridging Grant Awardees here  

 Victorian medical emergency company Medical Developments International emerges as global leader

A Victorian emergency medicine company has risen to become a global leader, thanks to its range of respiratory medications. Offering new devices for asthma and chronic obstructive pulmonary disease (COPD), Medical Developments International (MDI), is turning its attention…

LBT Innovations Receives 2017 SA Science Excellence Award for Collaboration

LBT Innovations Ltd (LBT) has been awarded the 2017 SA Science Excellence Award for “Excellence in Research Collaboration”. The award recognises excellence in developing a world leading intelligent medical device in South Australia, and the collaboration between the…

VivaGel® BV demonstrated statistically significant efficacy in two pivotal phase 3 trials

VivaGel® BV consistently resulted in reduced rates of BV recurrence by the primary efficacy endpoint and five secondary efficacy measures, and delayed time to first recurrence VivaGel® BV resulted in sustained benefits 3 months after cessation of treatment…

Home

News & opinion

Member Directory

Events